(Total Views: 153)
Posted On: 10/04/2022 2:01:19 PM
Post# of 144791
$NBIO has enrolled the first patient of the fifth and final cohort of its Phase I clinical trial to evaluate Pritumumab ("PTB"
as a treatment for Primary and Metastatic Brain Cancers.
Sean Carrick, Nascent CEO, explains, "We are enthusiastically encouraging anyone interested in screening for the trial to do so in a timely manner. This cohort of patients will likely be the final one in this trial, and new patient enrollment will cease until our Phase II research gets underway."
as a treatment for Primary and Metastatic Brain Cancers. Sean Carrick, Nascent CEO, explains, "We are enthusiastically encouraging anyone interested in screening for the trial to do so in a timely manner. This cohort of patients will likely be the final one in this trial, and new patient enrollment will cease until our Phase II research gets underway."
(0)
(0)Scroll down for more posts ▼
